Tracey L. Evans, MD, associate professor of Clinical Medicine at Penn Medicine, discusses the challenges associated with immunotherapy for the treatment of patients with lung cancer.

Although immunotherapy is showing promise in lung cancer, it is not for every patient. Dealing with the disappointment from both the patients and their families can be very difficult, says Evans.

Also, pseudo-progression is sometimes seen in the first-line setting with immune-based agents in this disease, adds Evans. If this seems to be occurring, switching to chemotherapy may be a viable option.

Videos

Tracey L. Evans, MD, associate professor of Clinical Medicine at Penn Medicine, discusses the challenges associated with immunotherapy for the treatment of patients with lung cancer.
 

Tracey Evans, MD

Articles

Dr. Evans on Challenges of Immunotherapy in Lung Cancer